Sinis-CI Loxo 1223403-58-4 manufacturers, et instructus

Loxo 1223403-58-4-CI

Description:

API nomen est scriptor	indication	innovator	Exitus patent Date (US)
Loxo 1223403-58-4-CI	oncology pharmacum	Loxo Oncology	Oct.21,2029

Mitte nobis inscriptio

Product Detail

Product Tags

FRUCTUS SINGULA

Maecenas vitae

IC50 low TRK familiaribus omnibus inhibitionis nanomolar conculcationem

Loxo receptor-CI est tropomyosin kinases (TRK) Matrix.

Et de cognatione TRK neurotrophin receptoribus et neurotrophin ligands ordinare cell augmentum et diversificantur salvos.

Herpesvirus hominis; prior in studio, Loxo enzyme enzyme inhibitionis target-off-CI quanquam erat contra a panel of non-unionem TRK kinases ad NM, glutamicum concentratione circa 1,000 ad KM. Results ostendit quod Loxo-CI L% praeceptum erat ut solum unum major non-TRK kinase, quod erat TNK2 Domini DLXXVI cum IC50 nm sollicitatur. Sed et alios pertinet hERG nec praeceptum nec prolongentur QT quad observationis [I].

In vivo Animal studio invenitur, quod Loxo-CI inhibere poterat, ut in vivo tumore augmentum. Cellulis infusum per similitudines murium sex Athymic KM12 tractata sunt viva cum cotidie pro II weeks Loxo CI-et-dependens pondere tumorem praeceptum fuit, in qua ostendetur ordo facultatem ad inhibere in-CI-Loxo vivo tumore augmentum Dei [I].

Iudicium orci, tempus non multicenter A-dose propagationis eorum studium solidae in patientibus proficiebat secretiori parte natium (ClinicalTrials.gov no. NCT02122913) deductusque in MMXIV ad aestimandas salute & PR de Loxo-CI. Semel aut bis cotidie pro XXVIII diebus dosed aegroti sunt continui in dosing escalating cohortes. Primae PK et salus data liberum indicant plasma-CI est ad biologicam sui Loxo gradus pertinet ad inhibere TRK oncogenes concentratione. In hoc studio, patientes estote et solus primo ostendit TRK fusione cum vidisset procedere curatio et celeri tumor orci in Loxo-CI [I].

Reference:
[I] Doebele R. et al. An Oncogenic NTRK posuere eget est patientia, in Mollis-TEXTUM Ad Herpesvirus hominis cum Tropomyosin-Related Nicotiana tabacum Loxo inhibitor-CI. Oct Discov.2015 cancer, V (X): 1049-57.

Description

Larotrectinib (Loxo-CI) In ATP-competitive est oris, et electionem selectivam inhibitor-related tropomyosin beta (TRK) receptoribus domo et humilis concentratione nanomolar L% machinationem inhibendi ius contra omnes tribus isoforms (TRKA, B et C).

Orci iudicio

Number NCT	Sponsor	conditione,	satus Date	tempus
NCT03025360	Bayer	Usu quod receptavit posuere eget NTRK
NCT02637687	Bayer	Solidum Usu hospitio posuere eget NTRK	December XVI, MMXV	Tempus I \| II tempus
NCT02122913	Bayer	Solidum Usu hospitio posuere eget NTRK	May IV, MMXIV	I tempus
NCT03213704	National Cancri Instituti (NCI)	Advanced malignum solidum naturae \| Recurrentes Ependymoma \| Recurrentes Ewing Herpesvirus hominis + periphericorum Primitiva Neuroectodermal tumor \| Recurrentes glioma \| Recurrentes Hepatoblastoma \| Recurrentes Langerhans Cell Histiozytosis \| Recurrentes malignum Quo Magni Commen Cell tumor \| Recurrentes malignum glioma \| Recurrentes malignum solidum naturae \| Recurrentes Medulloblastoma \| Recurrentes Neuroblastoma \| Recurrentes, non Hodgkin lymphoma \| Recurrentes Osteogenesis imperfecta \| Recurrentes Rhabdoid tumor \| Recurrentes Rhabdomyosarcoma \| Recurrentes textus mollis Herpesvirus \| Refractory Ependymoma \| Refractory Ewing Herpesvirus hominis + periphericorum Primitiva Neuroectodermal tumor \| Refractory glioma \| Refractory Hepatoblastoma \| Refractory Langerhans Cell Histiozytosis \| Refractory malignum Quo Magni Commen Cell tumor \| Refractory Humana malignas glioma \| Refractory Neoplasma malignum solidum \| Refractory Neuroblastoma \| Refractory Non Hodgkin lymphoma \| Refractory Osteogenesis imperfecta \| Refractory prima Ratio nervorum naturae Central \| Refractory Rhabdoid tumor \| Refractory Rhabdomyosarcoma \| tumor Wilms	July XXIV, MMXVII	II tempus
NCT02465060	National Cancri Instituti (NCI)	Advanced malignum solidum naturae \| Morbositates vesicae Ulcus \| pectore Ulcus \| Ceruicis Ulcus \| Colonia Ulcus \| Colorectal Ulcus \| Endometrial Ulcus \| Esophageal Ulcus \| CARDIACUS Ulcus \| glioma \| capite et collo Lupus Carcinoma \| Renibus Ulcus \| Iecoris et Intrahepatic duct Ulcus \| pathologica pulmonis: Ulcus \| lymphoma \| malignum Tuba naturae \| Carcinoma \| Ovarian Ulcus \| pancreatic cancer Ulcus \| Plasma Pure Cell Herpesvirus \| prostatae Ulcus \| Recto Ulcus \| Recurrentes Morbositates vesicae Ulcus \| Recurrentes pectore Ulcus \| Recurrentes Ceruicis Ulcus \| Recurrentes Colonia Ulcus \| Recurrentes Colorectal Ulcus \| Recurrentes Esophageal Ulcus \| Recurrentes, CARDIACUS Ulcus \| Recurrentes glioma \| Recurrentes capite et collo Lupus Carcinoma \| Recurrentes, hepatis Ulcus \| Recurrentes, pathologica pulmonis: Ulcus \| Recurrentes lymphoma \| Recurrentes malignum solidum naturae \| Recurrentes Carcinoma \| Recurrentes Ovarian Ulcus \| Recurrentes pancreatic cancer Ulcus \| Recurrentes Plasma Pure Cell Herpesvirus \| Recurrentes prostatae Ulcus \| Recurrentes Recto Ulcus \| recurrentes Ulcus cutis \| recurrentes, glandula Lupus Carcinoma \| Recurrentes corpus vteri cancer \| Refractory lymphoma \| Refractory Neoplasma malignum solidum \| Refractory Cell Herpesvirus Plasma Pure \| Ulcus cutis \| glandula Ulcus \| corpus vteri cancer	August XII, MMXV	II tempus
NCT03834961	Group Children's Oncology \| National Cancri Instituti (NCI)	Virus naturae \| Infantile fibrosarcoma \| Recurrentes acutus Leukemia \| Refractory acutus Leukemia \| solidum naturae	September XVIII, MMXIX	II tempus
NCT04142437	Bayer	Advanced secundum locum, aut tumor Metastasico Solidum est quod receptavit NTRK posuere eget Gene	III Aprilis, MMXX
NCT03155620	National Cancri Instituti (NCI)	Advanced malignum solidum naturae \| Ann Arbor Scaena III Non Hodgkin lymphoma \| Ann Arbor Scaena IV Non Hodgkin lymphoma \| Histiocytic Herpesvirus \| Xanthogranuloma juvenile \| Langerhans Cell Histiozytosis \| malignum glioma \| Recurrentes Puer Rhabdomyosarcoma \| Recurrentes Ependymoma \| Recurrentes Ewing Herpesvirus \| Recurrentes glioma \| recurrentes Hepatoblastoma \| recurrentes Langerhans Cell Histiozytosis \| recurrentes malignum Quo Magni Commen Cell tumor \| recurrentes malignum solidum naturae \| recurrentes Medulloblastoma \| recurrentes Neuroblastoma \| recurrentes Non Hodgkin lymphoma \| recurrentes Osteogenesis imperfecta \| recurrentes periphericorum Primitiva Neuroectodermal tumor \| recurrentes prima Central nervous system naturae \| recurrentes Rhabdoid Tumour \| Recurrentes Herpesvirus hominis textus mollis \| Refractory Herpesvirus hominis Ewing \| Refractory glioma \| Refractory Hepatoblastoma \| Refractory Langerhans Cell Histiozytosis \| Refractory malignum germinis tumor Cell \| Refractory Neoplasma malignum solidum \| Refractory Medulloblastoma \| Refractory Neuroblastoma \| Refractory Non Hodgkin lymphoma \| Refractory Osteogenesis imperfecta \| refra ctory periphericorum Primitiva Neuroectodermal tumor \| Refractory Prima Central nervous system naturae \| Refractory Rhabdoid tumor \| Refractory Rhabdomyosarcoma \| Rhabdoid tumor \| Scaena III Osteogenesis imperfecta AJCC v7 \| Scaena III textus mollis Herpesvirus hominis AJCC v7 \| spectacula theatrica II Osteogenesis imperfecta AJCC v7 \| spectacula theatrica II textus mollis Herpesvirus hominis AJCC v7 \| Tempus IVA Osteogenesis imperfecta AJCC v7 \| Tempus IVB Osteogenesis imperfecta AJCC v7 \| tumor Wilms	July XXIV, MMXVII	II tempus